Effects of Estrogen therapy on Ghrelin and Leptin level in overweight/obese women with surgical menopause

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210831004

Enrollment

Registered

2021-08-31

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ghrelin and leptin level in postmenopausal women after two different route of estrogen therapy Estrogen Ghrelin Leptin Obese Bodyweight Body composition

Interventions

Oestrogel 1 metered dose (1.5mg),Estradiol valerate (Progynova) 1mg/day orally

Active Comparator Drug,Active Comparator Drug

Transdermal estrogen therapy,Oral estrogen therapy

Eligibility

Sex/Gender

Female

Age

41 Years to 60 Years

Inclusion criteria

Inclusion criteria: Postmenopausal women who have undergone bilateral oophorectomy before menopause Within 10 years since menopause BMI in overweight/obese range (Asian criteria) No history of menopausal hormonal therapy use or wash out more than 3 months before recruitment

Exclusion criteria

Exclusion criteria: Premature ovarian insufficiency (onset of menopause before 40 years) History of cancer, chemotherapy or radiation History of Type 1 or type 2 diabetes, hypertrigleceridemia, immunocompromised host, abnormal thyroid function Contraindication to hormonal therapy (stroke, venous thromboembolism, coronary heart disease, breast cancer, drug hypersensitivity)

Design outcomes

Primary

Measure	Time frame
Ghrelin level 12 weeks Blood testing	—

Secondary

Measure	Time frame
Leptin level 12 weeks Blood testing,Appetite change 12 weeks Questionaire	—

Countries

Thailand

Contacts

Public ContactPimpat Chawarntunpipat

King Chulalongkorn Memorial Hospital

drpimpat.ch@gmail.com66859095277

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026